Isis upbeat on prospects for US Kynamro approval and promising pipeline
This article was originally published in Scrip
Following an upbeat second quarter earnings report on 6 August and guidance for the rest of the year, antisense drug developer Isis Pharmaceuticals announced an offering of $175 million of convertible senior notes to repurchase debt previously issued by the company, to repurchase or redeem existing convertible notes and for general expenses.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.